Success Metrics

Clinical Success Rate
100.0%

Based on 9 completed trials

Completion Rate
100%(9/9)
Active Trials
1(8%)
Results Posted
22%(2 trials)

Phase Distribution

Ph not_applicable
6
46%
Ph phase_4
1
8%
Ph phase_1
1
8%
Ph phase_2
3
23%
Ph early_phase_1
1
8%

Phase Distribution

2

Early Stage

3

Mid Stage

1

Late Stage

Phase Distribution12 total trials
Early Phase 1First-in-human
1(8.3%)
Phase 1Safety & dosage
1(8.3%)
Phase 2Efficacy & side effects
3(25.0%)
Phase 4Post-market surveillance
1(8.3%)
N/ANon-phased studies
6(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

9 of 9 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

13

all time

Status Distribution
Active(2)
Completed(9)
Other(2)

Detailed Status

Completed9
unknown2
Recruiting1
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
13
Active
1
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (8.3%)
Phase 11 (8.3%)
Phase 23 (25.0%)
Phase 41 (8.3%)
N/A6 (50.0%)

Trials by Status

recruiting18%
enrolling_by_invitation18%
completed969%
unknown215%

Recent Activity

Clinical Trials (13)

Drug Details

Intervention Type
DRUG
Total Trials
13